title: 70 Gy or more: which dose for which prostate cancer?
abstract: BACKGROUND
  Radical prostatectomy and radiotherapy are currently accepted treatment modalities for localized prostate cancer. Regarding radiotherapy, current evidence suggests that favorable treatment outcome critically depends on adequate radiation doses. However, the exact role of dose in relation to the individual risk profile is complex. In order to evaluate available data on radiation dose response relationships, in prostate cancer, a thorough and critical literature analysis was performed.
  
  
  METHODS
  Studies on dose response relationships from randomized trials, dose escalation trials, retrospective subgroup analyses and pooled data were identified by Pubmed and ISI web of sciences searches and were critically reviewed.
  
  
  CONCLUSIONS
  All available data suggest a clear dose response relationship for radiotherapy for localized prostate cancer. In low risk cases, most studies suggest that doses of 70-72 Gy are adequate. Dose escalations up to 78-80 Gy seem to be beneficial for intermediate risk patients. Due to confounding variables, the dose response curves for high-risk patients are less steep. The integration of dose escalation into a more comprehensive treatment protocol is difficult, since trials on the relative impact of either hormonal ablation or inclusion of adjuvant nodal regions on dose escalation are missing.
authors.affiliation: Department of Radiation Oncology, University of Tübingen, Hoppe Seyler Str. 3, 72076, Tübingen, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Ganswindt
authors.forename: F
authors.initials: F
authors.lastname: Paulsen
authors.forename: A G
authors.initials: AG
authors.lastname: Anastasiadis
authors.forename: A
authors.initials: A
authors.lastname: Stenzl
authors.forename: M
authors.initials: M
authors.lastname: Bamberg
authors.forename: C
authors.initials: C
authors.lastname: Belka
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000097:blood / Q000401:mortality / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D017430:Prostate-Specific Antigen